For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular medications such as Ozempic.
The findings, published Friday in JAMA Health Forum, suggest that blockbuster medications such as Novo Nordisk A/S’s Ozempic and Wegovy and Eli Lilly & Co.’s Mounjaro and Zepbound may actually be ...
Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...
Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...
Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.
Despite the skepticism and outrage over Robert F. Kennedy Jr.’s nomination to head the Department of Health and Human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback